Par Sues FDA For Yanking Gout Drug's 180-Day Exclusivity

The Third Circuit affirmed a Pennsylvania federal court’s dismissal of Mylan’s antitrust suit over the acne medication Doryx, finding that the generics maker failed to establish that Warner Chilcott and Mayne had sufficient market power in the relevant market. More

Rate this item
(0 votes)
Login to post comments

Newsletter Subscription

Joomla forms builder by JoomlaShine

IP2017 Banner 380x280

IP Era 300x250

Go to top